Healthcare

January 16, 2019

Ebola: AHF Africa Urges WHO to Accelerate Response; Faults African Union’s Silence

(AETOS Wire) -- AIDS Healthcare Foundation (AHF), the largest global AIDS organization operating in 43 countries, is profoundly concerned with the rise in new Ebola cases in the Democratic Republic of Congo and fear of its spread if uncontained. The August 1, 2018 outbreak is now the second deadliest in history and seems to be spiralling out of control amid insecurity in the country. This follows after the devastating 2014 outbreak which claimed over 11,000 lives in West Africa, including two of AHF’s doctors. As of Jan 2, 2019, the total number of confirmed and probable patients is estimated to have surpassed 600, with 368 deaths and......

January 9, 2019

ResMed Completes $225 Million Acquisition of Propeller Health

(AETOS Wire)-- ResMed (NYSE: RMD) (ASX: RMD), a leader in cloud-connected medical devices and out-of-hospital software-as-a-service (SaaS) business solutions, today announced it has completed its acquisition of Propeller Health, a digital therapeutics"...

January 9, 2019

Takeda Completes Acquisition of Shire, Becoming a Global, Values-Based, R&D-Driven Biopharmaceutical Leader

8 months from deal announcement to deal close
Strong shareholder support with high approval rates on Takeda (89.1%) and Shire (99.8%)
Integration planning well underway

(AETOS Wire)-- Takeda Pharmaceutical"...

January 8, 2019

Vocera Introduces New Wearable Smartbadge Purpose-Built for Healthcare

(AETOS Wire)-- Vocera Communications, Inc. (NYSE:VCRA), a recognised leader in clinical communication and workflow solutions, today announced the launch of a new category of wearable communication devices that enables clinician agility and accelerates"...

January 8, 2019

Factory CRO and Boston Biomedical Associates Announce Merger

(AETOS Wire) -- Factory-CRO Group, a leading global contract research organization (CRO) focused on medical devices and in vitro diagnostics (IVDs), and Boston Biomedical Associates (BBA) a premier full-service Medical Device/Biotechnology CRO and Consultancy based in the United States announce that they have merged the organizations. The merger further advances the shared strategic vision to become the leading Global Medical Device and Medical Technology focused CRO. Following the recent acquisitions of MileStone Research Organization, Five Corners, and Clinical Device Group the Factory-CRO Group now has specialized operations and expertise......

January 8, 2019

Cambridge Epigenetix announces programme for routine screening and detection of colorectal cancer and other common tumours

(AETOS Wire) -- Cambridge Epigenetix Ltd, a pioneer in the development and application of epigenetic technologies, today announces its discovery and development programme for a test to detect colorectal and other cancers. This follows completion"...

January 6, 2019

GE Healthcare, Vanderbilt University Medical Center Partner for Safer, More Precise Immunotherapy Cancer Treatment

(AETOS Wire)-- GE Healthcare and Vanderbilt University Medical Center (VUMC) today announced a five-year partnership to enable safer and more precise cancer immunotherapies. Multiple diagnostic tools will be developed to help predict both the efficacy"...

January 6, 2019

The Promise of Care – Emirates Hospital’s Journey to Triumph

In today’s time, as hospitals and health systems continue to consolidate, the ability to improve care delivery is increasingly important. Believing in this philosophy and deploying it at all stages of operation, Emirates Hospital in Jumeirah has grown exponentially to a sprawling"...

January 4, 2019

Takeda Notes Court Sanction of the Scheme of Arrangement with Respect to the Acquisition of Shire plc

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) notes Shire plc’s (“Shire”) announcement that the Royal Court of Jersey (the “Jersey Court”) has today sanctioned the scheme of arrangement (the “Scheme”) pursuant to which the proposed acquisition of Shire by Takeda (the “Acquisition”) is being implemented. As previously announced, it is expected that the Scheme will become effective, and that closing of the Acquisition will take place, on January 8, 2019, when a copy of the Jersey Court order is delivered to the registrar of companies in Jersey. There has been......

January 4, 2019

Boehringer Ingelheim Exercises Option on Second Hepatic Disease Target From Research Collaboration with Dicerna

Boehringer Ingelheim and Dicerna Pharmaceuticals (NASDAQ: DRNA), a leading developer of investigational RNA interference (RNAi) therapeutics, today announced that Boehringer Ingelheim has exercised an option to receive exclusive rights to a second hepatic disease target emerging from its research collaboration and license agreement with Dicerna. The collaboration, established in October 2017, aims to discover and develop novel GalXC™ RNAi therapeutics for the treatment of chronic liver diseases, with an initial focus on nonalcoholic steatohepatitis (NASH), a devastating disease for which there is no approved treatment. The option is the......